We are live on ! Find out more
MDCO

Medicines Co
MDCO

Delisted

MDCO was delisted on the 3rd of January, 2020.

166 hedge funds and large institutions have $1.9B invested in Medicines Co in 2014 Q1 according to their latest regulatory filings, with 24 funds opening new positions, 59 increasing their positions, 65 reducing their positions, and 38 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding in top 10

Funds holding in top 10: 22 (0)

4% less call options, than puts

Call options by funds: $13.6M | Put options by funds: $14.1M

9% less repeat investments, than reductions

Existing positions increased: 59 | Existing positions reduced: 65

9% less funds holding

Funds holding: 182166 (-16)

27% less capital invested

Capital invested by funds: $2.6B → $1.9B (-$710M)

37% less first-time investments, than exits

New positions opened: 24 | Existing positions closed: 38

Holders
166
Holders Change
-16
Holders Change %
-8.79%
% of All Funds
4.79%
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.06%
New
24
Increased
59
Reduced
65
Closed
38
Calls
$13.6M
Puts
$14.1M
Net Calls
-$499K
Net Calls Change
-$3.02M
Name Holding Trade Value Shares
Change
Change in
Stake
SCM
101
Stevens Capital Management
Pennsylvania
$1.05M +$1.22M +36,996 New
CAM
102
Capstone Asset Management
Texas
$955K -$8.6K -260 -0.8%
RJA
103
Raymond James & Associates
Florida
$946K +$275K +8,304 +33%
MAM
104
Martingale Asset Management
Massachusetts
$936K +$235K +7,107 +28%
FQ
105
First Quadrant
California
$926K -$139K -4,200 -11%
LSERS
106
Louisiana State Employees Retirement System
Louisiana
$853K +$16.5K +500 +2%
AIP
107
Ameritas Investment Partners
Nebraska
$829K +$786K +23,743 +435%
SIM
108
Spark Investment Management
New York
$781K -$470K -14,200 -34%
MAA
109
Managed Account Advisors
New Jersey
$769K -$55.4K -1,674 -6%
ARTA
110
A.R.T. Advisors
New York
$721K -$995K -30,076 -54%
Thrivent Financial for Lutherans
111
Thrivent Financial for Lutherans
Minnesota
$669K +$8.27K +250 +1%
Nomura Holdings
112
Nomura Holdings
Japan
$667K -$53.1K -1,606 -6%
Susquehanna International Group
113
Susquehanna International Group
Pennsylvania
$652K -$776K -23,461 -51%
NLGIA
114
Nippon Life Global Investors Americas
New York
$646K -$2.64M -79,780 -78%
U
115
UBS
Switzerland
$616K -$216K -6,522 -23%
AQR Capital Management
116
AQR Capital Management
Connecticut
$598K -$347K -10,472 -33%
Adage Capital Partners
117
Adage Capital Partners
Massachusetts
$550K +$640K +19,352 New
DC
118
Deere & Company
Illinois
$546K +$59.1K +1,785 +10%
UBS AM
119
UBS AM
Illinois
$534K +$23.2K +700 +4%
TC
120
TFS Capital
Pennsylvania
$532K -$5.78M -174,786 -90%
PNC Financial Services Group
121
PNC Financial Services Group
Pennsylvania
$529K -$94.3K -2,851 -13%
SFP
122
Santa Fe Partners
New Mexico
$466K +$543K +16,413 New
PI
123
PineBridge Investments
New York
$463K -$41.2K -1,245 -7%
PA
124
Profund Advisors
Maryland
$441K -$188K -5,680 -27%
MERSOM
125
Municipal Employees' Retirement System of Michigan
Michigan
$441K +$513K +15,500 New

MDCO Hedge Fund Activity: Q1 2014 in Review

166 of the 3,462 institutional investors tracked by Wall St. Rank reported a position in Medicines Co (MDCO) for Q1 2014, worth a combined $1.9B — down 27% from $2.6B a quarter earlier.

Sellers outnumbered buyers: 38 funds closed out of MDCO and 24 opened new positions — a net loss of 14 holders — while 65 trimmed existing stakes and 59 added.

The largest buyer was Fidelity Investments, adding an estimated $51.7M. The largest seller was PFM Health Sciences, exiting entirely with an estimated $81.7M sold.

  • 166 institutional investors held Medicines Co (MDCO) as of Q1 2014, down from 182 in Q4 2013.
  • Funds reported $1.9B of Medicines Co stock for Q1 2014, down 27% quarter-over-quarter.
  • 24 funds opened new Medicines Co positions in Q1 2014 and 38 closed out, a net change of -14 holders.
  • The largest Medicines Co buyer in Q1 2014 was Fidelity Investments, an estimated $51.7M added.
  • The largest Medicines Co seller in Q1 2014 was PFM Health Sciences, an estimated $81.7M sold.

Based on aggregated 13F filings for Q1 2014.